Delayed hepatocellular carcinoma model for end‐stage liver disease exception score improves disparity in access to liver transplant in the United States
Julie K. Heimbach, Ryutaro Hirose, Peter G. Stock, David P. Schladt, Hui Xiong, Jiannong Liu, Kim M. Olthoff, Ann Harper, Jon J. Snyder, Ajay K. Israni, Bertram L. Kasiske, W. Ray Kim – 16 January 2015 – The current system granting liver transplant candidates with hepatocellular carcinoma (HCC) additional Model for End‐Stage Liver Disease (MELD) points is controversial due to geographic disparity and uncertainty regarding optimal prioritization of candidates. The current national policy assigns a MELD exception score of 22 immediately upon listing of eligible patients with HCC.